iShares US Pharmaceuticals ETF Stock Forecast, Price & News

-2.54 (-1.36 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,956 shs
Average Volume7,476 shs
Market Capitalization$369.33 million
P/E RatioN/A
Dividend Yield1.39%
30 days | 90 days | 365 days | Advanced Chart
Receive IHE News and Ratings via Email

Sign-up to receive the latest news and ratings for iShares US Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer iShares
Fund NameiShares US Pharmaceuticals ETF
Tax ClassificationRegulated Investment Company
Inception Date5/1/2006
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason

Fund Focus

Asset ClassEquity
BenchmarkDow Jones US Select Pharmaceuticals Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$369.10 million
Average Daily Volume$6,272.00

ETF Expenses

Management Fee0.44%
Other Expenses0.00%
Total Expenses0.44%
Fee Waiver0.00%
Net Expenses0.44%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Lead Market MakerIMC Chicago

Geographic Exposure of IHE

Currency Exposure of IHE

Sector Exposure of IHE

Industry Exposure of IHE

speech bubbles
speech bubbles

iShares US Pharmaceuticals ETF (NYSEARCA:IHE) Frequently Asked Questions

What stocks does MarketBeat like better than iShares US Pharmaceuticals ETF?

Wall Street analysts have given iShares US Pharmaceuticals ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iShares US Pharmaceuticals ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has iShares US Pharmaceuticals ETF's stock price been impacted by Coronavirus?

iShares US Pharmaceuticals ETF's stock was trading at $138.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IHE shares have increased by 33.2% and is now trading at $184.6647.
View which stocks have been most impacted by COVID-19

Is iShares US Pharmaceuticals ETF a good dividend stock?

iShares US Pharmaceuticals ETF pays an annual dividend of $2.59 per share and currently has a dividend yield of 1.39%.
View iShares US Pharmaceuticals ETF's dividend history.

Who are iShares US Pharmaceuticals ETF's key executives?

iShares US Pharmaceuticals ETF's management team includes the following people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees (Age 78)
  • Michael Arthur Latham, President, Trustee (Age 51)
  • Jack Gee, Chief Financial Officer, Treasurer (Age 57)
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • Amy Schioldager, Executive Vice President (Age 56)
  • Ira P. Shapiro, Vice President, Chief Legal Officer (Age 52)
  • Matt Tucker, Vice President
  • Eilleen M. Clavere, Secretary (Age 61)
  • Cecilia H. Herbert, Independent Trustee (Age 68)
  • Charles A. Hurty, Independent Trustee (Age 73)

What other stocks do shareholders of iShares US Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares US Pharmaceuticals ETF investors own include United Parcel Service (UPS), CVS Health (CVS), Genuine Parts (GPC), Intel (INTC), Kinder Morgan (KMI), Wells Fargo & Company (WFC), Archer-Daniels-Midland (ADM), (AEP), BP (BP) and Campbell Soup (CPB).

What is iShares US Pharmaceuticals ETF's stock symbol?

iShares US Pharmaceuticals ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "IHE."

Who are iShares US Pharmaceuticals ETF's major shareholders?

iShares US Pharmaceuticals ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Royal Bank of Canada (2.47%), Morgan Stanley (2.11%), Murphy Capital Management Inc. (0.95%), UBS Group AG (0.55%), Envestnet Asset Management Inc. (0.50%) and Fisher Asset Management LLC (0.44%).

Which major investors are selling iShares US Pharmaceuticals ETF stock?

IHE stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Morgan Stanley, Proequities Inc., Ameriprise Financial Inc., UBS Group AG, Fisher Asset Management LLC, Kestra Advisory Services LLC, and JPMorgan Chase & Co..

Which major investors are buying iShares US Pharmaceuticals ETF stock?

IHE stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada, United Asset Strategies Inc., Flow Traders U.S. LLC, Total Clarity Wealth Management Inc., RMR Wealth Builders, Allworth Financial LP, Piscataqua Savings Bank, and Citigroup Inc..

How do I buy shares of iShares US Pharmaceuticals ETF?

Shares of IHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iShares US Pharmaceuticals ETF's stock price today?

One share of IHE stock can currently be purchased for approximately $184.66.

How much money does iShares US Pharmaceuticals ETF make?

iShares US Pharmaceuticals ETF has a market capitalization of $369.33 million.

What is iShares US Pharmaceuticals ETF's official website?

The official website for iShares US Pharmaceuticals ETF is www.iShares.com.

Where are iShares US Pharmaceuticals ETF's headquarters?

iShares US Pharmaceuticals ETF is headquartered at c/o SEI Investments Distribution Co., One Freedom Valley Drive, Oaks, 19456, United States.

This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.